Form 4: Tenaya Therapeutics' Chief Medical Officer Receives Stock Options and Restricted Stock Units

Chief Medical Officer of Tenaya Therapeutics, Whittemore Tingley, reports acquisition of stock options and restricted stock units.

Summary

• On February 23, 2024, Whittemore Tingley, the Chief Medical Officer of Tenaya Therapeutics, acquired 215,000 stock options with an exercise price of $5.22, and 35,000 restricted stock units (RSUs).
• The stock options vest monthly over four years, while the RSUs vest semi-annually starting August 15, 2024.
• Following these transactions, Tingley directly owns 215,000 stock options and 108,534 shares of common stock (including shares issuable upon vesting of RSUs).

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of equity is a standard practice and generally viewed favorably as it aligns management's interests with shareholders.

Positives

• The grant of stock options and RSUs aligns the Chief Medical Officer's interests with those of the shareholders.
• The vesting schedules encourage long-term commitment from the executive.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the granted equity.

Industry Context

Stock option and RSU grants are common practice in the biotech industry to incentivize and retain key executives.

Comparison to Industry Standards

• Equity compensation packages for CMOs in biotech companies of similar size to Tenaya Therapeutics typically include a mix of stock options and restricted stock units.
• Vesting schedules are generally structured to incentivize long-term performance, often over a 3-4 year period, which aligns with the vesting schedule described in the document.
• Comparable companies such as MyoKardia (prior to its acquisition by Bristol Myers Squibb) and Cytokinetics have used similar equity compensation strategies for their executive teams.

Stakeholder Impact

• Shareholders may view the equity grants positively as they incentivize management to increase shareholder value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates